Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."

"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."

-Patients without favorable/intermediate characteristics.

"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."

-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.

Patients without favorable/intermediate characteristics and without matched related donor.